Tricuspid Insufficiency Treatment Market Players:
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Labcor Laboratorios Ltda.
- LivaNova, plc
- Sorin S.p.A.
- Cyberonics, Inc.
- Hologic, Inc.
- Corcym UK Limited
- Intuitive Surgical
- Sonova Holding AG
- Hill-Rom Holdings Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of tricuspid insufficiency treatment is assessed at USD 829.47 million.
The global tricuspid insufficiency treatment market size was valued at around USD 778.33 million in 2025 and is projected to grow at a CAGR of more than 7.3%, reaching USD 1.57 billion revenue by 2035.
By 2035, the Europe region in the tricuspid insufficiency treatment market is expected to secure a 32% share, sustained by the expanding use of tricuspid function therapy across major countries, especially Germany, and increasing investments in cardiac-care device research.
Key players in the market include Labcor Laboratorios Ltda., LivaNova, plc, Sorin S.p.A., Cyberonics, Inc., Hologic, Inc., Corcym UK Limited, Intuitive Surgical, Sonova Holding AG.
